Gender disparity seen with renal cell carcinoma management

The findings suggest that drug therapies targeting the NOTCH1 gene may serve as an alternative treatment option for patients with kidney cancer in whom surgery is not recommended.

The supplemental new drug application is supported by findings from the LITESPARK-005 trial.

The phase 1/2 Oncorella-1 trial is expected to enroll up to 40 patients with advanced kidney cancer who are on dialysis due to renal failure.

A Cleveland Clinic study found that TKIs in the neoadjuvant setting are associated with greater use of partial nephrectomy when treating patients diagnosed with renal masses in a solitary kidney.

The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.

Patients in the phase 3 LITESPARK-005 trial were randomized to belzutifan or everolimus after receiving both a PD-1/L1 inhibitor and a VEGF-TKI for their renal cell carcinoma.